BACKGROUND: Parathyroid failure is the most common complication after total thyroidectomy but permanent impairment of the parathyroid function is unusual. Limited data is available assessing long-term follow-up, quality of life and complications occurring in patients with permanent hypoparathyroidism (PH). We aimed to assess the incidence of complications derived from PH status, their influence on the quality of life perceived by PH patients and its relation to standard medical treatment with calcium salts and active vitamin D analogues. METHODS: Cross-sectional observational study of consecutive patients undergoing total thyroidectomy who developed PH and were followed at least twice a year at a referral endocrine surgery unit. PH was defined as intact parathyroid hormone (iPTH) levels <13 pg/mL and the need for replacement therapy with calcium and/or vitamin D for at least 1 year after surgery. Quality of life was assessed using the SF-36 questionnaire. Data regarding doses and type of vitamin D analogues and calcium supplementation, serum calcium fluctuations, bone densitometry and renal ultrasound were recorded. RESULTS: The cohort included 32 patients (3 male/29 female) with a mean age of 51.2±15.2 years. The mean follow-up was 78±68 months and the total follow-up length was 70,080 PH patient/days. Five (15.6%) patients showed a decreased renal function. At least one clinical adverse event was observed in 18 (56.3%) patients. There was a slight decrease of the punctuation in the SF-36 questionnaire for the perceived quality of life that was only significant for the emotional role. CONCLUSIONS: PH and its treatment carry a mild to moderate burden of illness if followed closely. During a mean follow-up of nearly 6 years, only half of the patients suffered a relevant clinical event with little impact on their quality of life.
BACKGROUND: Parathyroid failure is the most common complication after total thyroidectomy but permanent impairment of the parathyroid function is unusual. Limited data is available assessing long-term follow-up, quality of life and complications occurring in patients with permanent hypoparathyroidism (PH). We aimed to assess the incidence of complications derived from PH status, their influence on the quality of life perceived by PH patients and its relation to standard medical treatment with calcium salts and active vitamin D analogues. METHODS: Cross-sectional observational study of consecutive patients undergoing total thyroidectomy who developed PH and were followed at least twice a year at a referral endocrine surgery unit. PH was defined as intact parathyroid hormone (iPTH) levels <13 pg/mL and the need for replacement therapy with calcium and/or vitamin D for at least 1 year after surgery. Quality of life was assessed using the SF-36 questionnaire. Data regarding doses and type of vitamin D analogues and calcium supplementation, serum calcium fluctuations, bone densitometry and renal ultrasound were recorded. RESULTS: The cohort included 32 patients (3 male/29 female) with a mean age of 51.2±15.2 years. The mean follow-up was 78±68 months and the total follow-up length was 70,080 PH patient/days. Five (15.6%) patients showed a decreased renal function. At least one clinical adverse event was observed in 18 (56.3%) patients. There was a slight decrease of the punctuation in the SF-36 questionnaire for the perceived quality of life that was only significant for the emotional role. CONCLUSIONS: PH and its treatment carry a mild to moderate burden of illness if followed closely. During a mean follow-up of nearly 6 years, only half of the patients suffered a relevant clinical event with little impact on their quality of life.
Entities:
Keywords:
Permanent hypoparathyroidism (PH); complications; quality of life; thyroidectomy; treatment
Authors: John P Bilezikian; Aliya Khan; John T Potts; Maria Luisa Brandi; Bart L Clarke; Dolores Shoback; Harald Jüppner; Pierre D'Amour; John Fox; Lars Rejnmark; Leif Mosekilde; Mishaela R Rubin; David Dempster; Rachel Gafni; Michael T Collins; Jim Sliney; James Sanders Journal: J Bone Miner Res Date: 2011-10 Impact factor: 6.741
Authors: Jens Bollerslev; Lars Rejnmark; Claudio Marcocci; Dolores M Shoback; Antonio Sitges-Serra; Wim van Biesen; Olaf M Dekkers Journal: Eur J Endocrinol Date: 2015-08 Impact factor: 6.664
Authors: Wiebke Arlt; Christian Fremerey; Frank Callies; Martin Reincke; Peter Schneider; Wolfgang Timmermann; Bruno Allolio Journal: Eur J Endocrinol Date: 2002-02 Impact factor: 6.664
Authors: Karen K Winer; Chia Wen Ko; James C Reynolds; Karen Dowdy; Meg Keil; Donna Peterson; Lynn H Gerber; Charles McGarvey; Gordon B Cutler Journal: J Clin Endocrinol Metab Date: 2003-09 Impact factor: 5.958
Authors: Marianne C Astor; Kristian Løvås; Aleksandra Debowska; Erik F Eriksen; Johan A Evang; Christian Fossum; Kristian J Fougner; Synnøve E Holte; Kari Lima; Ragnar B Moe; Anne Grethe Myhre; E Helen Kemp; Bjørn G Nedrebø; Johan Svartberg; Eystein S Husebye Journal: J Clin Endocrinol Metab Date: 2016-05-17 Impact factor: 5.958
Authors: Guillermo Ponce de León-Ballesteros; David Velázquez-Fernández; F Javier Hernández-Calderón; Carlos Bonilla-Ramírez; Rafael H Pérez-Soto; Juan Pablo Pantoja; Mauricio Sierra; Miguel F Herrera Journal: World J Surg Date: 2019-07 Impact factor: 3.352
Authors: Juan J Díez; Emma Anda; Julia Sastre; Begoña Pérez Corral; Cristina Álvarez-Escolá; Laura Manjón; Miguel Paja; Marcel Sambo; Piedad Santiago Fernández; Concepción Blanco Carrera; Juan C Galofré; Elena Navarro; Carles Zafón; Eva Sanz; Amelia Oleaga; Orosia Bandrés; Sergio Donnay; Ana Megía; María Picallo; Cecilia Sánchez Ragnarsson; Gloria Baena-Nieto; José Carlos Fernández-García; Beatriz Lecumberri; Manel Sahún de la Vega; Ana R Romero-Lluch; Pedro Iglesias Journal: Gland Surg Date: 2020-10
Authors: José Gil Martinez; Miguel González; Quiteria Hernández; María Angeles Rodríguez; Nuria Torregrosa; Elena Gil; Pedro Antonio Cascales; Miguel Angel Delgado; Joan Sancho; Victor Lopez-Lopez; Jose Manuel Rodriguez Journal: Laryngoscope Investig Otolaryngol Date: 2022-03-09